Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia

Shigematsu, Akio; Tanaka, Junji; Suzuki, Ritsuro; Atsuta, Yoshiko; Kawase, Takakazu; Ito, Yoichi M.; Yamashita, Takuya; Fukuda, Takahiro; Kumano, Keiki; Iwato, Koji; Yoshiba, Fumiaki; Kanamori, Heiwa; Kobayashi, Naoki; Fukuhara, Takashi; Morishima, Yasuo; Imamura, Masahiro

Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia

Shigematsu, Akio; Tanaka, Junji; Suzuki, Ritsuro et al.

International Journal of Hematology, 2011, 94(5), 463-471

Permalink : https://hdl.handle.net/2115/47739

このアイテムのアクセス数:1,770件（2026-02-09 11:53 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
IJH94-5_463-471	pdf	311 KB	1,906

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/47739
タイトル	Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia
著者	Shigematsu, Akio ; Tanaka, Junji ; Suzuki, Ritsuro ; Atsuta, Yoshiko ; Kawase, Takakazu ; Ito, Yoichi M. ; Yamashita, Takuya ; Fukuda, Takahiro ; Kumano, Keiki ; Iwato, Koji ; Yoshiba, Fumiaki ; Kanamori, Heiwa ; Kobayashi, Naoki ; Fukuhara, Takashi ; Morishima, Yasuo ; Imamura, Masahiro
著者名 Shigematsu, Akio
著者名 Tanaka, Junji
著者名 Suzuki, Ritsuro
著者名 Atsuta, Yoshiko
著者名 Kawase, Takakazu
著者名 Ito, Yoichi M.
著者名 Yamashita, Takuya
著者名 Fukuda, Takahiro
著者名 Kumano, Keiki
著者名 Iwato, Koji
著者名 Yoshiba, Fumiaki
著者名 Kanamori, Heiwa
著者名 Kobayashi, Naoki
著者名 Fukuhara, Takashi
著者名 Morishima, Yasuo
著者名 Imamura, Masahiro
言語	英語
キーワード	Acute lymphoblastic leukemia
	Stem cell transplantation
	Conditioning regimen
	Medium-dose VP/CY/TBI
発行日	2011-11
出版者	Springer Japan
収録物名	International Journal of Hematology
巻(号)	94(5)
ページ	463-471
抄録	The choice of conditioning regimen before allogeneic stem cell transplantation (SCT) in patients with acute lymphoblastic leukemia (ALL) is important. We retrospectively compared outcomes of medium-dose VP-16/cyclophosphamide/total body irradiation (VP/CY/TBI) regimen and CY/TBI. Five hundred and twenty-nine patients (VP/CY/TBI: n = 35, CY/TBI: n = 494) who met all of the following criteria were compared: first time for SCT, aged 15-59 years; first or second complete remission at SCT; bone marrow or peripheral blood as stem cell source; and HLA phenotypically matched donor. Median age of the patients was 34 years, and patients who received VP/CY/TBI were younger (28 years vs. 34 years, P = 0.02). Cumulative incidences of relapse and non-relapse mortality (NRM) were higher for patients who received CY/TBI (P = 0.01 for relapse, P < 0.01 for NRM). After a median follow-up period of 36.9 months, 5-year overall survival (OS) rates were 82.2% in the VP/CY/TBI group and 55.2% in the CY/TBI group. OS, and disease-free survival (DFS) in the VP/CY/TBI group were shown to be significantly better by multivariate analysis [hazard ratio: 0.21 (95% confidence interval: 0.06-0.49) for DFS, hazard ratio: 0.25 (95% confidence interval: 0.08-0.59) for OS]. VP/CY/TBI was associated with a lower relapse rate and no increase in NRM, resulting in better survival than that in CY/TBI for adult ALL patients.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	The final publication is available at www.springerlink.com
PISSN	0925-5710
関連情報	PMID 22042561
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s12185-011-0944-2